Coyote Pharmaceuticals, Inc., has just announced that it is moving its lead compound, CNS-102, forward in clinical trials for ALS and Alzheimer’s disease. Coyote plans to begin the first phase of the clinical program in 2013, by treating people with ALS. In pre-clinical studies, CNS-102 showed promising results in animal models of neurodegenerative disease, rescuing neurons from death. Coyote hopes that these initial results will yield promising clinical trial results in humans. Coyote Pharmaceuticals was founded in 2009 and has a focus on neurodegenerative and orphan diseases.
Click here to read more.Share this: